Researchers randomized patients with advanced neuroendocrine tumors 2:1 to receive either cabozantinib or placebo.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/cabozantinib-improves-pfs-advanced-neuroendocrine-tumors-2025a10003s3?src=rss
Author :
Publish date : 2025-02-13 11:40:54
Copyright for syndicated content belongs to the linked Source.
